Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNM9C4
|
|||
| Drug Name |
ALN-RSV01
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Respiratory infection [ICD-11: CA07-CA4Z] | Phase 2 | [1] | |
| Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2 | [2] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HRSV Nucleoprotein messenger RNA (HRSV N mRNA) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00658086) Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00658086) Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). U.S. National Institutes of Health. | |||
| REF 3 | Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.